Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 2.5 to 2.
Financials
Financial year 2025
APOTHEEK LEFEVER - DE CLOEDT from Knokke-Heist, company number BE0421212996, closed financial year 2025 with a result of € 24,062 after tax. For that financial year APOTHEEK LEFEVER - DE CLOEDT recorded a gross margin of € 199,947 and equity of € 699,201. Compared with financial year 2024, the result moved from € 45,581 to € 24,062. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.
€ 699,201
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 24,062
▼ 47% vs 2024
Profit after tax over the fiscal year.
€ 484,936
▲ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 637,201.
People and assets in 2025
2
▼ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 145,767
▼ 29% vs 2024
€ 72,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 3,655
▼ 47% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 126,442
▲ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 18,242
▼ 32% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 194,701 | € 116,309 | € 278,041 | € 199,947 | ▼ 28% |
| Profit after taxes | € 34,610 | € -56,624 | € 45,581 | € 24,062 | ▼ 47% |
| Equity | € 686,183 | € 629,559 | € 675,140 | € 699,201 | ▲ 4% |
| Total debts | € 725,334 | € 673,211 | € 509,784 | € 482,323 | ▼ 5% |
| Cash | € 692,285 | € 280,327 | € 472,761 | € 484,936 | ▲ 3% |
| Land & buildings | € 101,194 | € 99,042 | € 78,274 | € 61,928 | ▼ 21% |
| Retained profit | € 624,183 | € 567,559 | € 613,140 | € 637,201 | ▲ 4% |
| Dividend | € 500,000 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 1,411,518 | € 1,302,770 | € 1,184,923 | € 1,181,524 | |
| Employees (FTE) | 2.3 | 2.5 | 2.2 | 2 | ▼ 0.2 |
Key figures of APOTHEEK LEFEVER - DE CLOEDT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to APOTHEEK LEFEVER - DE CLOEDT?
What happened at APOTHEEK LEFEVER - DE CLOEDT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Alfred Lefever stepped down as director. NBB
- Farmaks BV stepped down as director. NBB
- Sofie De Cloedt stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 24,062 (▼ 47% vs 2024). filed late Source: NBB ↗
- Alfred Lefever became a director. NBB
- Farmaks BV became a director. NBB
- Sofie De Cloedt became a director. NBB
- New establishment in Knokke-Heist. KBO
In short
From € 34,610 profit in 2022 to € 24,062 profit in 2025.
Paid € 24,124 in corporate taxes since 2022.
Best year ever: 2024, with € 45,581 profit.
On average € 100,000 of value added per employee in 2025.
A new publication or filing at APOTHEEK LEFEVER - DE CLOEDT? We notify you, reason included.
Follow APOTHEEK LEFEVER - DE CLOEDTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of FARMAKS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
APOTHEEK LEFEVER - DE CLOEDTThe shares are held by FARMAKS (98.7%).
Directors
According to the 2025 annual accounts
Alfred Lefever
Director
since 2023 · until 2029
since 2023 · until 2029
since 2023 · until 2029
Shareholders
98.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Dorpsstraat 110
8300 Knokke-Heist
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0421.212.996
- VAT number
- BE 0421.212.996
- Registered office
- Dorpsstraat 110, 8300 Knokke-Heist
- Names & denominations
- APOTHEEK LEFEVER - DE CLOEDT
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 24 December 1980
- Peppol
- Active · Active since 9 Sept 2024
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers